摘要
卵巢癌是女性生殖系统常见恶性肿瘤,患者病死率高,近年来发病率有上升趋势。卵巢癌具有发现晚、易复发和耐药等特点,寻找有效的治疗方法有重要意义。组蛋白甲基化是一种表观遗传修饰,由组蛋白甲基转移酶和去甲基化酶共同调控。组蛋白甲基化修饰异常与肿瘤的发生、发展密切相关,探讨组蛋白甲基转移酶和组蛋白去甲基化酶在卵巢癌中的作用对卵巢癌的靶向治疗有重要意义。本文就组蛋白甲基转移酶和组蛋白去甲基化酶在卵巢癌中作用及组蛋白甲基化修饰酶抑制剂在卵巢癌中临床应用的研究进展作一综述。
Ovarian cancer is a common malignant tumor of female reproductive system with high fatality rate.In recent years,the incidence rate has increased.Ovarian cancer has the characteristics of late detection,easy recurrence and drug resistance,so it is of great significance to explore effective treatment methods.Histone methylation,an epigenetic modification,is jointly regulated by histone-methyl transferase and histone demethylase.Abnormal histone methylation modification is closely correlated with the occurrence and development of tumors,therefore to study the roles of histone methyl transferase and histone demethylase in ovarian cancer is very important for the targeted treatment.This paper reviews the research progress of the roles of histone-methyl transferases and histone demethylases and the clinical application of histone methylation modifying enzyme inhibitors in ovarian cancer.
作者
屈函
董科显
傅松滨
QU Han;DONG Ke-xian;FU Song-bin(Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China,Laboratory of Medical Genetics of Harbin Medical University,Harbin,Heilongjiang 150081,China)
出处
《中华实用诊断与治疗杂志》
2021年第8期854-856,共3页
Journal of Chinese Practical Diagnosis and Therapy
基金
中国遗传资源保护与疾病防控教育部重点实验室开放课题(LPHGRDC2020-003)。
